SUBSCRIBE
SUBSCRIBE

Phase 2

BioForest
Clinical Catch-Up: May 25-29
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
May 29, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Following Phase II Failure, Ironwood and AbbVie Halt Development of Delayed-Release Linzess
Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.
May 29, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Startup ViralClear Drives Antiviral into Phase II for COVID-19 Following Significant Preclinical Results
ViralClear Chief Executive Officer Nick Spring told BioSpace that the preclinical work is “telling a very good story.”
May 28, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Neurotrope and NIH Launch Long-Term Trial of Bryostatin in Alzheimer’s
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
May 28, 2020
 · 
2 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CEPI-Backed Novavax Doses First Patients with COVID-19 Vaccine Candidate
The Maryland-based company has enrolled and dosed its first patients in a Phase I/II study.
May 26, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Press Releases
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
May 1, 2026
 · 
6 min read
Press Releases
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
May 1, 2026
 · 
5 min read
Press Releases
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
May 1, 2026
 · 
7 min read
Press Releases
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
April 30, 2026
 · 
6 min read
Press Releases
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
April 30, 2026
 · 
9 min read
Press Releases
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
April 30, 2026
 · 
3 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
April 30, 2026
 · 
7 min read
Press Releases
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
April 30, 2026
 · 
5 min read
Press Releases
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
April 30, 2026
 · 
7 min read
Press Releases
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
April 30, 2026
 · 
7 min read
Press Releases
Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
April 30, 2026
 · 
4 min read
Press Releases
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
April 30, 2026
 · 
6 min read
Press Releases
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
 · 
13 min read
Press Releases
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease
April 30, 2026
 · 
6 min read
Press Releases
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
April 30, 2026
 · 
5 min read
Press Releases
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
April 29, 2026
 · 
10 min read
Press Releases
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026
 · 
9 min read
Press Releases
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy’s Annual Meeting
April 29, 2026
 · 
2 min read
Press Releases
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
April 29, 2026
 · 
4 min read
Press Releases
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
April 29, 2026
 · 
11 min read
Load More